CO2019004102A2 - Vectores de citomegalovirus que provocan células t restringidas por moléculas del complejo mayor de histocompatibilidad e - Google Patents
Vectores de citomegalovirus que provocan células t restringidas por moléculas del complejo mayor de histocompatibilidad eInfo
- Publication number
- CO2019004102A2 CO2019004102A2 CONC2019/0004102A CO2019004102A CO2019004102A2 CO 2019004102 A2 CO2019004102 A2 CO 2019004102A2 CO 2019004102 A CO2019004102 A CO 2019004102A CO 2019004102 A2 CO2019004102 A2 CO 2019004102A2
- Authority
- CO
- Colombia
- Prior art keywords
- cause
- major histocompatibility
- histocompatibility complex
- complex molecules
- cells restricted
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 3
- 239000013598 vector Substances 0.000 title abstract 3
- 241000701022 Cytomegalovirus Species 0.000 title 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 title 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 title 1
- 108700011259 MicroRNAs Proteins 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 239000002679 microRNA Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662409840P | 2016-10-18 | 2016-10-18 | |
| PCT/US2017/057106 WO2018075591A1 (en) | 2016-10-18 | 2017-10-18 | Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019004102A2 true CO2019004102A2 (es) | 2019-07-10 |
Family
ID=62018862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0004102A CO2019004102A2 (es) | 2016-10-18 | 2019-04-24 | Vectores de citomegalovirus que provocan células t restringidas por moléculas del complejo mayor de histocompatibilidad e |
Country Status (22)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011143653A2 (en) | 2010-05-14 | 2011-11-17 | Oregon Health & Science University | Recombinant hcmv and rhcmv vectors and uses thereof |
| PT2691530T (pt) | 2011-06-10 | 2018-05-10 | Univ Oregon Health & Science | Glicoproteínas e vectores recombinantes cmv |
| PL2964769T3 (pl) | 2013-03-05 | 2019-03-29 | Oregon Health & Science University | Wektory cytomegalowirusa umożliwiające kontrolę ukierunkowania limfocytów T |
| AU2015289560B2 (en) | 2014-07-16 | 2018-09-27 | Oregon Health & Science University | Human cytomegalovirus comprising exogenous antigens |
| US20180298404A1 (en) | 2015-02-10 | 2018-10-18 | Oregon Health & Science University | Methods and compositions useful in generating non canonical cd8+ t cell responses |
| MA43285A (fr) | 2015-11-20 | 2018-09-26 | Univ Oregon Health & Science | Vecteurs cmv comprenant des éléments de reconnaissance des microarn |
| EP3529363B1 (en) * | 2016-10-18 | 2025-07-30 | Oregon Health & Science University | Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules |
| CN114025792A (zh) * | 2019-03-21 | 2022-02-08 | 21C生物公司 | 针对感染期间的致病性免疫激活细胞的疫苗 |
| US11077185B2 (en) | 2019-03-21 | 2021-08-03 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
| US10632186B1 (en) | 2019-03-21 | 2020-04-28 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
| WO2020247858A1 (en) * | 2019-06-07 | 2020-12-10 | Oregon Health & Science University | Hepatitis b virus-specific t cell responses |
| EP3980071A4 (en) * | 2019-06-07 | 2023-10-11 | Oregon Health & Science University | Tumor-associated antigen-specific t cell responses |
| BR112022003159A2 (pt) * | 2019-08-20 | 2022-05-17 | Univ Oregon Health & Science | Modulação de respostas de células t por ul18 de citomegalovirus humano |
| PH12022550490A1 (en) | 2019-08-29 | 2023-02-06 | Triad Nat Security Llc | Hepatitis b virus vaccines |
| KR20220116458A (ko) * | 2019-12-16 | 2022-08-23 | 오레곤 헬스 앤드 사이언스 유니버시티 | 다중-특이적 t 세포 수용체 |
| JP2024534178A (ja) | 2021-08-31 | 2024-09-18 | ヴィア・バイオテクノロジー・インコーポレイテッド | 結核ワクチン |
| US20240384296A1 (en) | 2021-08-31 | 2024-11-21 | Vir Biotechnology, Inc. | Recombinant hcmv vectors and uses thereof |
| EP4630027A1 (en) | 2022-12-09 | 2025-10-15 | DYS-Immune Therapeutics | Composite aids vaccine generating anti-hiv specific neutralizing antibodies and/or anti-hiv cytotoxic t cells |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| DE3853139T2 (de) | 1987-06-26 | 1995-06-14 | Syntro Corp | Rekombinanter, fremde gene enthaltender menschlicher cytomegalovirus und seine verwendung. |
| US5273876A (en) | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
| SG49046A1 (en) | 1991-07-05 | 1998-05-18 | American Cyanamid Co | Method for identifying non-essential genes of the human cytomegalovirus genome and for screening for inhibitors of human cytomegaloverirus |
| AU7192394A (en) | 1993-07-19 | 1995-02-20 | Cantab Pharmaceuticals Research Limited | Production method for preparation of disabled viruses |
| WO1995030019A1 (en) | 1994-04-29 | 1995-11-09 | Pharmacia & Upjohn Company | Feline immunodeficiency virus vaccine |
| US5846806A (en) | 1994-07-29 | 1998-12-08 | American Cyanamid Company | Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression |
| WO1996026267A1 (en) | 1995-02-21 | 1996-08-29 | Cantab Pharmaceuticals Research Limited | Viral preparations, vectors, immunogens, and vaccines |
| EP0820311A4 (en) | 1995-04-04 | 2002-09-25 | Cell Genesys Inc | TRANSPLANTATION OF GENETICALLY MODIFIED CELLS WITH LOW CLASS I PROTEIN RATES OF THE MAJOR HISTOCOMPATIBILITY COMPLEX ON THEIR SURFACE |
| EP0966301B1 (en) | 1996-07-31 | 2005-02-09 | Ortho-McNeil Pharmaceutical, Inc. | Identification of human cytomegalovirus genes involved in down-regulation of mhc class i heavy chain expression |
| US20030138454A1 (en) | 1997-06-09 | 2003-07-24 | Oxxon Pharmaccines, Ltd. | Vaccination method |
| DE19733364A1 (de) | 1997-08-01 | 1999-02-04 | Koszinowski Ulrich H Prof | Verfahren zur Klonierung eines großen Virusgenoms |
| AU3910097A (en) | 1997-08-05 | 1999-03-01 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Live recombinant vaccine comprising inefficiently or non-replicating vir us |
| US7204990B1 (en) | 2000-11-28 | 2007-04-17 | Medimmune Vaccines, Inc. | Attenuation of cytomegalovirus virulence |
| CA2437201C (en) | 2001-02-02 | 2008-11-18 | Chemocentryx, Inc. | Methods and compositions useful for stimulating an immune response |
| EP1368465B1 (en) | 2001-02-21 | 2010-11-17 | The Wistar Institute Of Anatomy And Biology | Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates |
| GB0122232D0 (en) | 2001-09-14 | 2001-11-07 | Medical Res Council | Gene expression |
| BR0212619A (pt) | 2001-09-20 | 2004-08-17 | Glaxo Group Ltd | Sequência de nucleotìdeo, vetor, proteìna, composição farmacêutica, dispositivo de liberação intradérmica, método para tratar um paciente que sofre de uma doença ou é suscetìvel a ela, uso de uma sequência de nucleotìdeo, e, processo para a produção de um nucleotìdeo |
| US20030118568A1 (en) | 2001-12-18 | 2003-06-26 | Board Of Trustees Of The University Of Arkansas | Viral stealth technology to prevent T cell-mediated rejection of xenografts |
| JP2005523942A (ja) | 2002-04-30 | 2005-08-11 | アヴィオル セラピューティクス インコーポレイテッド | 免疫療法のためのアデノウイルスベクター |
| DE10232322A1 (de) | 2002-07-16 | 2004-07-29 | Hahn, Gabriele, Dr. | Viral kodierte CxC determinieren den Gewebetropismus von HCMV |
| US7407744B2 (en) | 2003-07-25 | 2008-08-05 | The Regents Of The University Of California | Cytomegalovirus gene function and methods for developing antivirals, anti-CMV vaccines, and CMV-based vectors |
| EP1766096B1 (en) | 2004-05-25 | 2013-01-02 | Oregon Health and Science University | Hiv vaccination usingand hcmv-based vaccine vectors |
| EP1602676A1 (en) | 2004-06-01 | 2005-12-07 | SOLVAY (Société Anonyme) | Catalytic compositions |
| WO2006004661A1 (en) | 2004-06-25 | 2006-01-12 | Medimmune Vaccines, Inc. | Recombinant human cytomegalovirus and vaccines comprising heterologous antigens |
| WO2006125983A1 (en) | 2005-05-23 | 2006-11-30 | Oxxon Therapeutics Ltd | Compositions for inducing an immune response against hepatitis b |
| US8765146B2 (en) | 2005-08-31 | 2014-07-01 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
| US20100142823A1 (en) | 2007-03-07 | 2010-06-10 | Ze Wang | 2d partially parallel imaging with k-space surrounding neighbors based data reconstruction |
| WO2009023386A2 (en) | 2007-07-06 | 2009-02-19 | Trubion Pharmaceuticals, Inc. | Binding peptides having a c-terminally disposed specific binding domain |
| EP2215117B2 (en) | 2007-10-30 | 2018-01-10 | Genentech, Inc. | Antibody purification by cation exchange chromatography |
| US8883995B2 (en) | 2009-03-06 | 2014-11-11 | Icahn School Of Medicine At Mount Sinai | Live attenuated influenza virus vaccines comprising microRNA response elements |
| KR101793615B1 (ko) * | 2009-04-30 | 2017-11-03 | 오스페달레 산 라파엘 에스.알.엘. | 유전자 벡터 |
| MX2012007489A (es) | 2009-12-23 | 2012-11-29 | 4Antibody Ag | Miembros enlazadores para citomegalovirus. |
| CN102844663B (zh) | 2010-01-27 | 2016-01-06 | 俄勒冈健康科学大学 | 基于巨细胞病毒的免疫原性制剂 |
| EP2550362B1 (en) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
| SG185121A1 (en) | 2010-05-05 | 2012-11-29 | Christian Thirion | Vaccine against beta-herpesvirus infection and use thereof |
| WO2011143653A2 (en) | 2010-05-14 | 2011-11-17 | Oregon Health & Science University | Recombinant hcmv and rhcmv vectors and uses thereof |
| PT2691530T (pt) | 2011-06-10 | 2018-05-10 | Univ Oregon Health & Science | Glicoproteínas e vectores recombinantes cmv |
| WO2013040320A1 (en) | 2011-09-16 | 2013-03-21 | Oregon Health & Science University | Methods and kits used in identifying microrna targets |
| US20130156808A1 (en) | 2011-11-22 | 2013-06-20 | Stipan Jonjic | Vaccine comprising beta-herpesvirus |
| JP2016501023A (ja) | 2012-12-04 | 2016-01-18 | メルク・シャープ・アンド・ドーム・コーポレーションＭ | 条件付き複製ウイルスベクター |
| PL2964769T3 (pl) | 2013-03-05 | 2019-03-29 | Oregon Health & Science University | Wektory cytomegalowirusa umożliwiające kontrolę ukierunkowania limfocytów T |
| AU2015289560B2 (en) | 2014-07-16 | 2018-09-27 | Oregon Health & Science University | Human cytomegalovirus comprising exogenous antigens |
| EP3048114A1 (en) | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
| US20180298404A1 (en) | 2015-02-10 | 2018-10-18 | Oregon Health & Science University | Methods and compositions useful in generating non canonical cd8+ t cell responses |
| MA43285A (fr) | 2015-11-20 | 2018-09-26 | Univ Oregon Health & Science | Vecteurs cmv comprenant des éléments de reconnaissance des microarn |
| EP3474889A4 (en) * | 2016-06-22 | 2020-04-29 | International AIDS Vaccine Initiative, Inc. | RECOMBINANT CYTOMEGALOVIRUS VECTORS FOR USE AS TUBERCULOSIS VACCINES |
| CN110291402B (zh) | 2016-06-27 | 2023-09-01 | 朱诺治疗学股份有限公司 | 鉴定肽表位的方法、结合此类表位的分子和相关用途 |
| EP3529363B1 (en) | 2016-10-18 | 2025-07-30 | Oregon Health & Science University | Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules |
-
2017
- 2017-10-18 EP EP17862978.8A patent/EP3529363B1/en active Active
- 2017-10-18 CN CN201780064422.7A patent/CN110036112B/zh active Active
- 2017-10-18 BR BR112019007982A patent/BR112019007982A2/pt not_active Application Discontinuation
- 2017-10-18 CA CA3040303A patent/CA3040303A1/en active Pending
- 2017-10-18 CR CR20190205A patent/CR20190205A/es unknown
- 2017-10-18 MA MA046588A patent/MA46588A/fr unknown
- 2017-10-18 KR KR1020197013148A patent/KR102604486B1/ko active Active
- 2017-10-18 MX MX2019004518A patent/MX2019004518A/es unknown
- 2017-10-18 AU AU2017346788A patent/AU2017346788A1/en not_active Abandoned
- 2017-10-18 JP JP2019520801A patent/JP2019531745A/ja active Pending
- 2017-10-18 PE PE2019000824A patent/PE20190840A1/es unknown
- 2017-10-18 IL IL266011A patent/IL266011B2/en unknown
- 2017-10-18 WO PCT/US2017/057106 patent/WO2018075591A1/en not_active Ceased
- 2017-10-18 SG SG11201903340TA patent/SG11201903340TA/en unknown
- 2017-10-18 EA EA201990937A patent/EA201990937A1/ru unknown
- 2017-10-18 UA UAA201904893A patent/UA126860C2/uk unknown
- 2017-10-18 US US15/786,847 patent/US10532099B2/en active Active
- 2017-10-18 TN TNP/2019/000124A patent/TN2019000124A1/en unknown
-
2019
- 2019-04-08 DO DO2019000086A patent/DOP2019000086A/es unknown
- 2019-04-17 CL CL2019001054A patent/CL2019001054A1/es unknown
- 2019-04-24 CO CONC2019/0004102A patent/CO2019004102A2/es unknown
- 2019-05-07 EC ECSENADI201931754A patent/ECSP19031754A/es unknown
- 2019-11-26 US US16/696,403 patent/US11305015B2/en active Active
-
2022
- 2022-10-21 JP JP2022169043A patent/JP7478794B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019004102A2 (es) | Vectores de citomegalovirus que provocan células t restringidas por moléculas del complejo mayor de histocompatibilidad e | |
| MX2017009538A (es) | Antigenos de citomegalovirus y su uso. | |
| MX2022006513A (es) | Constructos de expresion y metodos para dise?ar geneticamente levadura metilotrofica. | |
| DK3276811T3 (da) | Opladninsgssystem, opladningsfremgangsmåde og strømadapter | |
| MX2023003253A (es) | Metodos y composiciones para atenuar respuestas inmunes anti-vector de transferencia viral. | |
| MX2016013512A (es) | Sistemas y metodos para el uso simultaneo del espectro dentro del espectro usado activamente. | |
| MX384364B (es) | Anticuerpos anti-pd-l1 y sus usos de diagnóstico. | |
| EP3472305A4 (en) | GENETICALLY MODIFIED TREG CELLS | |
| CL2016002849A1 (es) | Oligómeros y conjugados de oligómeros | |
| HUE047988T2 (hu) | Nukleáris receptor modulátorok (ROR) gyulladásos és autoimmun betegségek kezelésére | |
| EP3403023C0 (fr) | Guide optique amélioré et système optique | |
| BR112017005040A2 (pt) | aparelho e sistema | |
| EP3795123C0 (en) | MEDICAL WEIGHING SYSTEMS | |
| DK3253863T3 (da) | Bioreaktorsystem til celledyrkning | |
| KR102318115B9 (ko) | 세포 대량배양 시스템 | |
| DK3500661T3 (da) | Cellekulturindsats og anordning til kultivering af celler | |
| IL259761A (en) | Imaging system unit cell and methods for dynamic range imaging | |
| EP3731353A4 (en) | LASER MODULE AND LASER SYSTEM | |
| MX2020004133A (es) | Oligosacaridos inmunomoduladores. | |
| EP3556764A4 (en) | NUCLEOSIDE DERIVATIVE AND USE FOR IT | |
| FR3040246B1 (fr) | Laser terahertz, source terahertz et utilisation d'un tel laser terahertz | |
| DK3274710T3 (da) | Forbedrede assays til måling af styrken af humane retinale pigmentepitel (rpe)-celler og fotoreceptorprogenitorer | |
| EP3691009A4 (en) | FUEL CELL SYSTEM AND FUEL CELL SYSTEM CONTROL METHOD | |
| EP3446117A4 (en) | SELECTION, EXPANSION AND USE OF IMMUNOCELLS | |
| BR112018014940A2 (pt) | combinação de herbicida |